Skip to main content
Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
122.92
-3.48 (-2.75%)
At close: Mar 28, 2025, 4:00 PM
125.00
+2.08 (1.69%)
After-hours: Mar 28, 2025, 5:42 PM EDT

Jazz Pharmaceuticals Revenue by Segment
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Neuroscience
2.66B 2.63B 2.64B 2.71B 2.76B 2.80B 2.80B 2.76B
Neuroscience Growth
-3.68% -5.92% -5.85% -1.92% 1.99% 5.89% 10.92% 18.22%
Oncology
1.09B 1.07B 1.04B 1.02B 965.36M 928.30M 905.92M 873.84M
Oncology Growth
13.26% 15.16% 15.23% 16.18% 12.64% 13.42% 20.40% 19.08%

Oncology Revenue Breakdown
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Rylaze Enrylaze
411.11M 417.19M 411.05M 394.23M 373.45M 342.11M 313.37M 281.66M
Rylaze Enrylaze Growth
10.08% 21.95% 31.17% 39.97% 40.58% 60.76% 124.07% 228.93%
Zepzelca
316.00M 308.15M 297.45M 289.53M 287.49M 279.82M 277.76M 269.91M
Zepzelca Growth
9.92% 10.13% 7.09% 7.27% 9.40% 5.92% 10.30% 9.36%
Defitellio Defibtrotide
210.00M 191.91M 192.60M 184.00M 173.57M 175.29M 183.88M 194.29M
Defitellio Defibtrotide Growth
20.99% 9.48% 4.74% -5.30% -11.51% -14.24% -7.04% -1.84%
Vyxeos
156.26M 151.77M 142.82M 147.50M 130.85M 131.09M 130.92M 127.98M
Vyxeos Growth
19.42% 15.78% 9.09% 15.25% -1.23% -4.38% -2.78% -4.54%

Neroscience Revenue Breakdown
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Xywav
1.41B 1.35B 1.31B 1.27B 1.22B 1.14B 1.05B 958.43M
Xywav Growth
15.77% 18.46% 24.80% 32.82% 41.60% 50.85% 62.56% 79.05%
Epidiolex
938.00M 900.15M 855.28M 845.47M 811.84M 794.35M 767.41M 736.40M
Epidiolex Growth
15.54% 13.32% 11.45% 14.81% 12.26% 15.57% 23.47% 58.83%
Xyrem
291.25M 358.24M 455.83M 569.73M 710.51M 841.43M 951.09M 1.02B
Xyrem Growth
-59.01% -57.42% -52.07% -44.17% -33.08% -24.40% -19.25% -19.38%
Sativex
18.84M 18.88M 15.31M 19.67M 19.25M 17.85M 19.18M 16.83M
Sativex Growth
-2.13% 5.81% -20.21% 16.90% 14.92% -9.09% 9.93% 32.41%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.